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ABSTRACT
Background: Little evidence on the validity of simple
and widely applicable tools to predict mortality in
patients with chronic obstructive pulmonary disease
(COPD) exists.
Objective: To conduct a large international study to
validate the ADO index that uses age, dyspnoea and
FEV1 to predict 3-year mortality and to update it in
order to make prediction of mortality in COPD patients
as generalisable as possible.
Design: Individual subject data analysis of 10
European and American cohorts (n=13 914).
Setting: Population-based, primary, secondary and
tertiary care.
Patients: COPD GOLD stages I–IV.
Measurements: We validated the original ADO index.
We then obtained an updated ADO index in half of our
cohorts to improve its predictive accuracy, which in
turn was validated comprehensively in the remaining
cohorts using discrimination, calibration and decision
curve analysis and a number of sensitivity analyses.
Results: 1350 (9.7%) of all subjects with COPD (60%
male, mean age 61 years, mean FEV1 66% predicted)
had died at 3 years. The original ADO index showed
high discrimination but poor calibration (p<0.001 for
difference between predicted and observed risk). The
updated ADO index (scores from 0 to 14) preserved
excellent discrimination (area under curve 0.81, 95%
CI 0.80 to 0.82) but showed much improved
calibration with predicted 3-year risks from 0.7%
(95% CI 0.6% to 0.9%, score of 0) to 64.5% (61.2%
to 67.7%, score of 14). The ADO index showed higher
net benefit in subjects at low-to-moderate risk of
3-year mortality than FEV1 alone.
Interpretation: The updated 15-point ADO index
accurately predicts 3-year mortality across the COPD
severity spectrum and can be used to inform patients
about their prognosis, clinical trial study design or
benefit harm assessment of medical interventions.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is among the leading causes of
death worldwide.1 2 Although the substantial
excess mortality associated with COPD is well
ARTICLE SUMMARY
Article focus
▪ We aimed to conduct a large international study
to validate the ADO index that uses age, dys-
pnoea and FEV1 to predict 3-year mortality and
to update it in order to make prediction of mor-
tality in chronic obstructive pulmonary disease
(COPD) patients as generalisable as possible.
Key messages
▪ The updated 15-point ADO index accurately pre-
dicts 3-year mortality across the COPD severity
spectrum (GOLD stage I–IV), settings (general
population, primary care and specialised care)
and geographical area.
▪ The updated ADO index can be used to inform
patients, clinical trial study design and benefit
harm assessment of medical interventions on a
population level or individual level.
▪ In addition, the ADO index could serve as a ref-
erence standard for risk prediction against which
the additional value of various biomarkers to
predict mortality could be assessed.
Strengths and limitations of this study
▪ The study includes a large sample size from 10
European and American cohorts and covers the
entire COPD severity spectrum, which increases
external validity.
▪ The study uses information readily available in
routine clinical practices.
▪ Focus on mortality and easily available predictors.
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recognised from a public health standpoint, relatively
little evidence is available on how to estimate the risk of
mortality for an individual patient. Tools to accurately
project the clinical course of the disease, including pre-
diction of outcomes such as mortality, exacerbations or
quality of life, would inform patients and their caregivers
about prognosis and allow for a better understanding of
the benefits and harms of possible treatments.3–6 Also,
tools that incorporate prognostic information from easily
available parameters could serve as reference against
which the additional prognostic value of biomarkers
could be assessed.
Current international COPD guidelines provide little
guidance on how to assess a patient’s prognosis.7 8 This
is likely due, in large part, to the scarcity of evidence on
how to accurately estimate prognosis in patients with
COPD; however, this is in contrast to other chronic
disease guidelines that have clear recommendations on
the use of prognostic indices to inform patients and to
guide treatment decisions.9–13 Prognostic indices for
COPD have recently received increased attention, but
have seen little application in clinical practice. This may
be because indices, to date, have either required infor-
mation not readily available in routine clinical practice,14
do not provide explicit outcome risks15 16 or have
received minimal validation.15–17 A recently developed
index, the ADO index, combines age, dyspnoea and
airflow obstruction to predict the risk of mortality. It
may have great potential for widespread application
because of its simplicity. However, formal testing of its
accuracy across a variety of COPD patient cohorts follow-
ing standard methods has not yet been done.6 18–21
The original index was derived in a cohort of moderate-
to-severe COPD patients from specialised care, there-
fore, it requires validation in larger and notably more
diverse COPD populations. We conducted such
large-scale international validation of the ADO index to
determine how well it predicts mortality for individual
subjects with COPD from diverse settings, and updated
the index as needed.
METHODS
Cohorts and patients
Investigators from 10 COPD and population-based
cohort studies in Europe and the Americas agreed to
collaborate in the International COPD Cohorts
Collaboration Working Group. These cohorts include
the Barmelweid cohort (Switzerland, clinic based),17 the
Basque study (Spain, clinic based),22 the Cardiovascular
Health Study (CHS, USA, population based),23 the
Copenhagen City Heart Study (CCHS, Denmark, popu-
lation based),24 the Jackson Heart Study ( JHS, USA,
population based),25 the Lung Health Study (LHS, USA,
clinic based),26 the cohort from which patients for the
National Emphysema Treatment Trial were recruited
(NETT, USA, clinic based),27 the Phenotype and Course
of COPD PAC-COPD Study (PAC-COPD, Spain, clinic
based),28 the PLATINO study (Uruguay, population
based),29 and the Quality of Life of COPD Study Group
(SEPOC, Spain, clinic based).30 Details about the
cohorts are provided in the online supplement (see
online supplementary appendix 1). From this inter-
national pool of cohorts we selected participants with at
least 40 years of age and with COPD defined by spirom-
etry as a post-bronchodilator (BD) FEV1/FVC≤0.7,
except for the CHS and CCHS cohorts where post-BD
was not available and pre-BD values were used. Thus,
our large pool of cohorts represents a heterogeneous
group of subjects, combining (1) COPD patients from
clinical cohorts and (2) subjects with evidence of airway
limitation from the population-based cohorts, but
without a confirmed diagnosis of COPD. Ethics Board
approval was obtained in all cohorts.
Mortality and candidate predictors of mortality
All-cause mortality at 3 years was defined as the
outcome. It was obtained from personal follow-up of
patients or relatives, national registries, or hospital
records, yielding no missing information with respect to
mortality. We considered potential predictors of mortal-
ity which are easy to obtain across diverse medical set-
tings. These variables included age, sex, smoking status,
prebronchodilator or postbronchodilator FEV1 as avail-
able, dyspnoea score (Medical Research Council
Dyspnea scale), respiratory signs and symptoms (cough,
sputum and wheezing), body mass index (BMI), asthma
and cardiovascular disease (CVD, which included ischae-
mic heart disease, stroke, congestive heart failure or per-
ipheral vascular disease). As in previous analyses,17 we
explicitly excluded potential predictors of mortality
which are more burdensome to measure such as exer-
cise capacity (eg, 6 min walked distance) or arterial
blood gases, since these are unlikely to be available con-
sistently in clinical practice outside academic centres.
Missing values were imputed using 10-fold multiple
imputation for each cohort, using the remaining vari-
ables as predictors.31 32 Methods used for collecting and
harmonising data, and for handling missing data are
detailed in the appendix (see online supplementary
appendices 2–4).
Statistical analysis
A detailed version of statistical analysis including sample
size assessment is available in the appendix (see online
supplementary appendix 5).
We first validated the original ADO index17 through
the assessment of its discrimination (area under curve)
and calibration (comparison of predicted vs observed
risk) properties in all subjects except for those included
in the original derivation cohort (ie, the Barmelweid
study).
In order to make the risk estimation tool as generalis-
able to different international populations as possible,
we then updated the ADO index following standardised
procedures that first included an updating or adjustment
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of the intercept only followed by, if necessary, more
extensive updates including model revision (refitting the
predictor-outcome associations) and model extension
(adding new predictors).21 32 Model refitting of the
ADO index was performed using all subjects from the
CCHS, LHS, NETT, PLATINO and PAC-COPD cohorts
(update cohort, n=10 221), applying logistic regression
with death as the outcome variable and age, dyspnoea
and FEV1 as predictors. Then the validation (discrimin-
ation and calibration) of the final updated ADO index
was done with the subjects from the Barmelweid study,
CHS, Basque Study, JHS and SEPOC cohorts (validation
cohort, n=3693). Thus, both update and validation sets
included a large number of subjects with COPD or
airflow limitation, diverse in terms of disease severity
(GOLD I–IV) and settings (general population, primary
care and specialised care). We translated the final model
into a simple-to-use 15-point scale.33
To further quantify the accuracy of the updated ADO
index, we performed a decision curve analysis that com-
pares the net benefit of different approaches. Net
benefit is defined as the difference between the propor-
tion of subjects that are correctly identified to be at or
above a certain risk threshold (eg, 5% risk) and the pro-
portion of subjects incorrectly identified to be at or
above that threshold. We focused on subjects with COPD
at low-to-moderate risk for 3-year mortality (<20%)
where most uncertainty about the balance between ben-
efits and harms of treatments may exist so that risk
thresholds may be specifically useful.34 35
Finally, we explored whether adding new predictors
(eg, CVD, BMI and sex) improved the updated (refit-
ted) models’ discrimination and calibration and we con-
ducted three sensitivity analyses that tested how
susceptible our results were to analytical approaches
taken. All analyses were repeated: (1) using multilevel
(rather than conventional) logistic regression analysis;
(2) excluding subjects with mild COPD (GOLD stage I)
and (3) excluding subjects with a physician diagnosis of
asthma from cohorts where only prebronchodilator spir-
ometry was available. We also considered restricting the
analyses to subjects with an FEV1/FVC ratio below their
lower limit of normal level according to local prediction
equations, but the number of subjects not fulfilling this
criterion was very low (<1%).
We conducted all analyses using Stata for Windows
(V.11.1, College Station, Texas, USA) and R, V.2.12
(R Foundation for Statistical Computing, Vienna,
Austria, 2011).
RESULTS
In total, 13 914 subjects with COPD (60% men) were
included in the analysis (table 1). On average, subjects
were approximately 61 years old, with moderate airflow
limitation and mild dyspnoea; however, there was a wide
range of disease severity within and across cohorts. The
majority of subjects were former or current smokers
(89%) and 22% had concomitant CVD. After 3 years
1350 (9.7%) subjects had died.
The original ADO index showed high discrimination
(see online supplementary appendix 6) but poor calibra-
tion with a substantial mismatch between predicted and
observed risks across the entire risk spectrum. Updating
the intercept only did not substantially improve this mis-
calibration. Therefore, we decided to update the ori-
ginal ADO index.
In the update cohort, the updated ADO model showed
very good agreement between predicted and observed
3-year mortality risk across 10 equally sized groups of sub-
jects with increasing predicted risk (figure 1: mean pre-
dicted risk 9.1%). More importantly, in the validation
cohort, the updated index still had good prediction
across all risk categories, in particular in subjects at mor-
tality risks below 20%. There was only a slight overpredic-
tion among subjects at very high risk. This validation did
not indicate a need for further adjustment of the inter-
cept or regression coefficients of the updated ADO
model, which indicated good generalisability across coun-
tries and settings. Discrimination was, as expected, some-
what lower in the validation cohort but still 0.73 (95% CI
0.70% to 0.76%). Further extensions of the updated
ADO index by adding CVD, BMI and sex did not substan-
tially improve the model’s discrimination or calibration,
even though all three predictors were significantly asso-
ciated with mortality in the multivariate model (all
p values <0.05). The area under the curve remained 0.85
in the update cohort and 0.74 in the validation cohort,
and the calibration also remained good (see online sup-
plementary appendix 7).
Tables 2 and 3 show the updated ADO index where the
strength of association of age, dyspnoea and FEV1 with
3-year mortality is reflected in the regression coefficients
and the corresponding integer point score. The 3-year
risks of mortality associated with ADO scores are shown
in table 4 and range from 0.7% (95% CI 0.6% to 0.9%)
with a score of zero to 64.5% (95% CI 61.2% to 67.7%) at
a point score of 14. The area under the curve of the
updated ADO index is 0.81 (95% CI 0.80% to 0.82%).
Figure 2A shows that, from 1% to 20% risk of 3-year
mortality, using the updated ADO index (regression
equation) is consistently more accurate to classify
patients correctly above or below certain risk thresholds
than using either of the three predictors alone.
Figure 2B shows the consequences of more accurate risk
classification. For example at a risk threshold of 5%,
using the ADO index would result in a reduction of the
number of patients classified incorrectly to be above 5%
by 33/100 subjects compared with considering all
patients to be above 5% (ie, without using any predic-
tors), and compared with using only FEV1 (18 per 100
subjects), age (24 per 100 subjects) or dyspnoea (10 per
100 subjects). At higher risk thresholds, the updated
ADO index and FEV1 perform similarly.
Discrimination, calibration and the analysis of
accuracy for risk thresholds remained essentially
Puhan MA, Hansel NN, Sobradillo P, et al. BMJ Open 2012;2:e002152. doi:10.1136/bmjopen-2012-002152 3
International validation of the ADO index in COPD
Table 1 Description of sociodemographic and clinical characteristics of 13 914 subjects with COPD from the cohorts
Barmelweid
cohort
Basque
study
Cardio-vascular
Health Study
Copenhagen
City Heart
Study
Jackson
Heart
Study
Lung
Health
Study
National
Emphysema
Treatment
Trial
PAC-COPD
Study
PLATINO
study
SEPOC
study
Total
Switzerland,
Europe
Spain,
Europe
USA, North
America
Denmark,
Europe
USA, North
America
USA, North
America
USA, North
America
Spain,
Europe
Uruguay,
South
America
Spain,
Europe
n=13914 n=231 n=106 n=2619 n=2287 n=419 n=5167 n=2252 n=342 n=173 n=318
Age (years),
mean (SD)
60.8 (11.6) 72.4 (8.8) 70.5 (8.9) 73.6 (5.9) 60.7 (9.4) 62.4 (11.0) 50.1 (5.7) 66.7 (6.3) 67.9 (8.6) 67.2 (11.3) 65.2 (9.2)
Sex: male, n
(%)
8324 (60) 138 (60) 104 (98) 1341 (51) 1235 (54) 184 (44) 3223 (62) 1366 (61) 318 (93) 97 (56) 318 (100)
Working status:
active, n (%)
5297 (63) n.a. n.a. n.a. n.a. 413 (99) 4538 (88) 178 (8) 61 (18) 63 (36) 51 (16)
Smoking
Never, n (%) 1452 (11) 9 (5) 0 (0) 930 (36) 215 (9) 215 (52) 0 (0) 12 (1) 2 (1) 57 (33) 12 (5)
Former,
n (%)
4751 (34) 138 (73) 82 (77) 1245 (48) 443 (19) 102 (25) 73 (1) 2240 (100) 220 (67) 60 (35) 148 (58)
Current,
n (%)
7590 (55) 41 (22) 24 (23) 444 (17) 1626 (71) 99 (24) 5094 (99) 0 (0) 109 (33) 56 (32) 97 (38)
Body mass
index(kg/m2),
mean(SD)
25.7 (4.5) 25.9 (6.1) 26.1 (4.9) 26.2 (4.8) 25.0 (4.2) 29.6 (7.5) 25.6 (3.9) 24.9 (4.2) 28.2 (4.7) 27.4 (5.3) 26.4 (4.2)
Dyspnoea
(MRC, 0–4),
mean (SD)
1.1 (1.3) 2.2 (1.2) 2.0 (0.6) 0.8 (1.1) 1.1 (1.3) 0.2 (0.6) 0.6 (0.8) 2.7 (1.0) 2.2 (1.0) 0.6 (0.6) 2.1 (1.5)
Cough, n (%) 4009 (59) n.a. n.a. 444 (17) n.a. 108 (26) 3259 (100) n.a. 138 (41) 60 (35) n.a.
Sputum, n (%) 4289 (52) n.a. n.a. 656 (25) 908 (40) 107 (26) 2400 (100) n.a. 172 (51) 46 (27) n.a.
Wheeze, n (%) 4352 (53) n.a. n.a. 187 (9) n.a. 73 (18) 3897 (75) n.a. 125 (37) 70 (40) n.a.
FEV1 (% pred),
mean (SD)*
65.9 (24.8) 45.1 (16.1) 46.9 (11.4) 77.3 (22.4) 70.5 (23.7) 71.2 (20.5) 77.8 (9.1) 27.5 (8.9) 52.4 (16.2) 84.3 (18.1) 45.0 (18.3)
Inhaler steroid
use, n (%)
1833 (33) - 103 (100) 55 (2) n.a. n.a. n.a. 1376 (61) 266 (79) 33 (19) n.a.
6-min walk
distance,
mean (SD)
357.8
(111.7)
363.1 (127.0) 442.9
(95.4)
n.a. n.a. n.a. n.a. 340.6 (106.3) 435.5 (90.6) n.a. n.a.
Asthma,† n (%) 920 (8) 0 (0) 0 (0) 148 (6) 246 (11) 74 (18) 373 (7) n.a. 30 (9) 49 (28) 0 (0)
Diabetes,†
n (%)
262 (7) 41 (18) n.a. n.a. 60 (3) 71 (19) n.a. n.a. 65 (19) 7 (4) 18 (6)
Continued
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unchanged in all sensitivity analyses (see online supple-
mentary appendix 8).
DISCUSSION
Our study showed that the updated ADO index, ranging
from 0 to 14, accurately predicts 3-year mortality in sub-
jects with COPD. We found that adding CVD, BMI or
sex does not significantly improve prediction of mortal-
ity when added to age, dyspnoea and FEV1. Importantly,
these results were consistent in sensitivity analyses and
across very diverse COPD populations. Based on these
results, the updated ADO index has the potential to
provide COPD patients with accurate prognostic infor-
mation on mortality.
The interest in prognostic assessment of COPD has
resulted in several prognostic tools.15–17 The latter had,
however, little impact on clinical guidelines or practice so
far. The current study overcomes potentially important
barriers to the use of previously published prognostic
tools by providing an extensive, international validation
of a simple tool. The first step of our analysis, the
large-scale validation of the original ADO index, showed
that mortality could not be predicted accurately but that
the combination of age, dyspnoea and FEV1 is highly dis-
criminative. Therefore, a more extensive update than just
an adjustment for different underlying risks was necessary
and we updated the entire regression model in our very
diverse update cohort that represented the entire disease
spectrum. The resulting updated ADO index showed
excellent calibration and discrimination in both the
update and validation cohorts. An additional adjustment
was not deemed necessary for the validation cohort,
which may be due to the great diversity of the update and
validation cohorts in terms of disease severity, clinical
setting and geographical area. Our results confirm that
CVD and low BMI are important comorbidities in COPD
patients and are significantly associated with mortality;
however, they did not provide additional accuracy in risk
prediction when added to age, dyspnoea and FEV1, as
shown by the fact that the performance of the ADO
index was not improved by adding CVD, sex and BMI to
the statistical model.
Informing patients about their prognosis is a core task
of clinicians. Patients with chronic disease are particu-
larly interested in the potential course of their disease in
order to better understand what a diagnosis such as
COPD implies for them. Important outcomes that char-
acterise prognosis are exacerbations, quality of life and
mortality.36 With the ADO index, we now provide a
simple tool that clinicians from any setting can use to
estimate the risk of mortality. We propose that such mul-
tivariable tools can also be used to balance the benefits
and harms of possible treatments since the benefit harm
balance depends heavily on the patients’ prognosis.4 37
Thus, estimation of prognosis is of key importance for
patients but also for policy makers, regulatory agencies
and clinical guideline developers. Our data suggest that
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Figure 1 Update and validation
of the ADO index in 13 914
subjects with chronic obstructive
pulmonary disease (COPD). The
upper part of the figure shows the
predictive performance of the
updated ADO index in 10 221
subjects with COPD from the
Copenhagen City Heart Study,
Lung Health Study, National
Emphysema Treatment Trial,
PLATINO and the Phenotype and
Course of COPD Study. The
calibration plot shows the
predicted and observed risks for
10 equally sized group with
increasing risk of 3-year mortality.
The discrimination plot shows the
area under the curve. The lower
part of the figure shows the
predictive performance of the
updated ADO index in the
validation cohort with 3693
subjects from the Cardiovascular
Health Study, Basque COPD
study, Jackson Heart Study,
Barmelweid Study and the Quality
of Life of Chronic Obstructive
Pulmonary Disease Study
(SEPOC).
Table 2 Regression coefficients and development of updated ADO index
Variable
Regression coefficients
βs per unit increase Categories
Reference values
Wij (mid point)
βs*
(Wij-*W1reference)
Risk score=βs*
(Wij-*W1reference)/B†
FEV1
(% predicted)
−0.0288
(SE 0.0023, p<0.0001)
≥81 87.0 (W2reference) 0
≥65–80 72.5 0.418 1
≥50–64 57.0 0.864 2
≥36–49 42.5 1.282 3
≤35 25.0 1.786 4
Dyspnoea
(mMRC, 0–4)
0.2585
(SE 0.0406, p<0.0001)
0 0 (W3reference) 0
1 1 0.259 1
2 2 0.517 1
3 3 0.776 2
4 4 1.034 3
Age (years) 0.0703
(SE 0.0048, p<0.0001)
40–49 44.5 (W4reference) 0
50–59 54.5 0.703 2
60–69 64.5 1.406 4
70–79 74.5 2.109 5
≥80 84.5 2.812 7
†1 Point is assigned per 15% in FEV1=coefficient of 0.40. Points rounded to the next integer. Constant of regression equation=−5.640.
MRC, Medical Research Council.
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the ADO index classifies patients more correctly above
or below certain risk thresholds than only FEV1, and this
gain is especially relevant in subjects with very low and
low risk of 3-year mortality where the benefit harm
balance may be unfavourable.3 4 Although most COPD
treatments are not prescribed to modify mortality risk,
but to reduce exacerbations, and improve symptoms and
quality of life, similar estimates for the benefit harm
balance could be made for patients at low risk for
exacerbations. Therefore, in the future, the ADO index
should be complemented by other widely validated risk
tools that make accurate projections about the risk for
important outcomes in COPD, including exacerbations
or worsening quality of life, in order to balance the ben-
efits and harms of possible treatments.
In addition, accurate prediction of mortality by the
ADO index can be used in clinical trials to base sample
size calculations on realistic estimates of expected event
rates, to target treatments to specific risk groups, for pre-
stratification or to adjust for potential baseline imbal-
ances. Also, the ADO index could be useful for the
evaluation of biomarkers. Currently, major studies are
being carried out to identify biomarkers that might help
to improve outcome prediction and response to treat-
ments. The use of such biomarkers in clinical practice
seems justified if they add significantly to the prediction
based on easily available information. The ADO index is
a simple tool that could serve as reference against which
the additional value of biomarkers to predict mortality
could be assessed. Therefore, the ADO index is likely to
be useful for both medical practice and research.
A limitation to the current study is the use of mortality
as the only assessed outcome, since COPD morbidity
includes other relevant outcomes such as exacerbations,
hospital admissions, or quality-of-life. Thus, our study
should be considered a simplification of the clinical
setting but it may pave the way for similar research evalu-
ating risk prediction of additional outcomes. Once risk
tools for various important outcomes and improved evi-
dence about benefit and harm of treatments to modify
these risks are available, informed decisions for provid-
ing the most appropriate care can be better supported.
Our study was confined to a limited number of readily
available predictors; therefore, variables with potential
relevance to mortality risk such as exacerbation fre-
quency or measures of exercise capacity were not
included. This may also be perceived as strength of our
study because it uses information readily available in
routine clinical practices, including primary care set-
tings, where most COPD patients are treated. Additional
strengths of our study include the already mentioned
large sample size and diversity of the populations. This
increases external validity, which in this context means
that recalibrations in populations different from those
included in our analyses do not seem necessary. Lastly,
by using decision curve analysis we looked beyond stand-
ard metrics for the performance of risk tools (discrimin-
ation and calibration) by providing an interpretation of
the risk model that refers to different risk thresholds
that may be used to inform treatment decisions.
In conclusion, the updated 15-point ADO index is a
simple tool that can be used in diverse settings to
inform patients and their caregivers about prognosis.
Using risk tools in clinical COPD research may also help
to design clinical trials and to inform policy makers,
regulatory agencies or guideline developers when esti-
mating the benefit harm balance and to serve as a refer-
ence standard for risk prediction against which the
Table 3 Assignment of points for the updated ADO index, compared with the original ADO index
Assignment of points 0 1 2 3 4 5 7
Updated ADO index
FEV1 (% predicted) ≥81 65–80 51–64 36–50 ≤35
Dyspnoea (mMRC, 0–4) 0 1–2 3 4
Age (in years) 40–49 50–59 60–69 70–79 ≥80
Original ADO index
FEV1 (% predicted) ≥65 36–64 ≤35
Dyspnoea (mMRC, 0–4) 0–1 2 3 4
Age (years) 40–49 50–59 60–69 70–79 80–89 ≥90
Table 4 The ADO index—prediction of 3-year mortality in
chronic obstructive pulmonary disease subjects
Three-year risk of mortality per ADO score in % (95% CI)
0 0.7 (0.6 to 0.9)
1 1.0 (0.9 to 1.2)
2 1.6 (1.3 to 1.8)
3 2.3 (2.0 to 2.6)
4 3.4 (3.0 to 3.7)
5 4.9 (4.5 to 5.4)
6 7.2 (6.7 to 7.7)
7 10.3 (9.7 to 10.9)
8 14.5 (13.8 to 15.3)
9 20.1 (19.1 to 21.1)
10 27.2 (25.8 to 28.6)
11 35.7 (33.7 to 37.7)
12 45.1 (42.6 to 47.7)
13 55.0 (52.0 to 58.0)
14 64.5 (61.2 to 67.7)
OR per 1 point increase in ADO index: 1.48 (95% CI 1.45 to 1.52).
Area under the curve: 0.81 (95% CI 0.80 to 0.82).
Puhan MA, Hansel NN, Sobradillo P, et al. BMJ Open 2012;2:e002152. doi:10.1136/bmjopen-2012-002152 7
International validation of the ADO index in COPD
additional value of various biomarkers to predict mortal-
ity could be assessed.
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